Targeted therapies have allowed for an individualized treatment approach in non-small-cell
lung cancer (NSCLC). The initial therapeutic decisions and success of targeted therapy …

Introduction: The rise of the personalized era in lung cancer prompted the evaluation of
novel diagnostic tools to overcome some of the limits of traditional tumor genotyping. Liquid …

Circulating tumor cells (CTC) count and characterization have been associated with poor
prognosis in recent studies. Our aim was to examine CTC count and its association with …

Background: The prognosis of early stage non-small cell lung cancer (NSCLC) is quite
disappointing and the benefits of adjuvant therapy are relatively small. Thus, there is an …

Lung cancer has become a paradigm for precision medicine in oncology, and liquid biopsy
(LB) together with radiomics may have a great potential in this scenario. They are both …

Purpose This study retrospectively investigated the clinical utility of 2-deoxy-18F-
fluorodeoxyglucose (18 F-FDG) positron emission tomography/computed tomography …

Background and objective: Circulating tumor cells (CTCs) can be classified into three
phenotypes based on epithelial-to-mesenchymal transition (EMT) markers, including …

Personalised treatment in oncology has seen great developments over the last decade, due
to both technological advances and more in-depth knowledge of radiobiological processes …

Background There is a risk of over investigation and delayed treatment in the work up of
solid nodules. Thus, the aim of our study was to develop and validate an integrated model …

Background A significant proportion of patients with clinical stage IA non-small cell lung
cancer (NSCLC) experience will recurrence and decreased survival after surgery. This study …